Clearance Rates
ZORYVE delivered proven and rapid results
See the results at Week 8
Primary
Endpoint
IGA Success*
Key Secondary
Endpoint
I-IGA Success†
~40% of patients achieved IGA Success at Week 8
(clear/almost clear + ≥2-grade improvement)‡1,3
§P<0.0001 vs vehicle.
Only Week 8 timepoint is included in the Prescribing Information
IGA Success rates at Week 8 were consistent regardless of baseline involvement
(mild, moderate, severe)‡3
~60% mean PASI improvement at just 8 weeks‡3
*IGA Success = clear/almost clear and a ≥2-grade improvement from baseline.
†I-IGA Success = clear/almost clear and a ≥2-grade improvement from baseline in intertriginous areas of the body.
‡Data from additional prespecified efficacy analyses from the DERMIS-1 and DERMIS-2 trials. These data are not in the Prescribing Information for ZORYVE.
PASI = Psoriasis Area and Severity Index
~70% of patients achieved I-IGA Success at Week 8
(clear/almost clear + ≥2-grade improvement)‡1,3
§P=0.0001 vs vehicle.
ǁP<0.0001 vs vehicle.
¶P<0.01 vs vehicle.
Only Week 8 timepoint is included in the Prescribing Information
Clinical trials for ZORYVE were the first and only Phase 3 trials to evaluate I-IGA Success with topical therapy for plaque psoriasis.
*IGA Success = clear/almost clear and a ≥2-grade improvement from baseline.
†I-IGA Success = clear/almost clear and a ≥2-grade improvement from baseline in intertriginous areas of the body.
‡Data from additional prespecified efficacy analyses from the DERMIS-1 and DERMIS-2 trials. These data are not in the Prescribing Information for ZORYVE.